Mostra i principali dati dell'item
Previous Bladder Cancer History in Patients with High-Risk, Non-muscle-invasive Bladder Cancer Correlates with Recurrence and Progression: Implications of Natural History
dc.creator | Mitrakas, L. P. | en |
dc.creator | Zachos, I. V. | en |
dc.creator | Tzortzis, V. P. | en |
dc.creator | Gravas, S. A. | en |
dc.creator | Rouka, E. C. | en |
dc.creator | Dimitropoulos, K. I. | en |
dc.creator | Vandoros, G. P. | en |
dc.creator | Karatzas, A. D. | en |
dc.creator | Melekos, M. D. | en |
dc.creator | Papavassiliou, A. G. | en |
dc.date.accessioned | 2015-11-23T10:39:45Z | |
dc.date.available | 2015-11-23T10:39:45Z | |
dc.date.issued | 2015 | |
dc.identifier | 10.4143/crt.2014.050 | |
dc.identifier.issn | 1598-2998 | |
dc.identifier.uri | http://hdl.handle.net/11615/31077 | |
dc.description.abstract | Purpose The purpose of this study was to assess the correlation of previous bladder cancer history with the recurrence and progression of patients with high-risk non-muscle-invasive bladder cancer treated with adjuvant Bacillus Calmette-Guerin (BCG) and to evaluate their natural history. Materials and Methods Patients were divided into two groups based on the existence of previous bladder cancer (primary, non-primary). A logistic regression analysis was used to identify the possible differences in the probabilities of recurrence and progression with respect to tumor history, while potential differences due to gender, tumor size (> 3 cm, < 3 cm), stage (pTa, T1), concomitant carcinoma in situ (pTis) and number of tumors (single, multiple) were also assessed. Univariate and multivariate models were employed. In addition, Kaplan-Meier survival analysis was used to compare recurrence-and progression-free survival between the groups. Results A total of 192 patients were included (144 with primary and 48 with non-primary tumors). The rates of recurrence and progression for patients with primary tumors were 27.8% and 12.5%, respectively. The corresponding percentages for patients with non-primary tumors were 77.1% and 33.3%, respectively. The latter group of patients displayed significantly higher probabilities of recurrence (p=0.000; 95% confidence interval [CI], 4.067 to 18.804) and progression (p=0.002; 95% CI, 1.609 to 7.614) in a univariate logistic regression analysis. Previous bladder cancer history remained significant in the multivariate model accounting for history, age, gender, tumor size, number of tumors, stage and concomitant pTis (p=0.000; 95% CI, 4.367 to 21.924 and p=0.002; 95% CI, 1.611 to 8.182 for recurrence and progression respectively). Kaplan-Meier curves revealed that the non-primary group hadreduced progression- and recurrence-free survival. Conclusion Previous non-muscle-invasive bladder cancer history correlates significantly with recurrence and progression in patients with high-risk non muscle-invasive disease treated with adjuvant BCG. | en |
dc.source | Cancer Research and Treatment | en |
dc.source.uri | <Go to ISI>://WOS:000357874900018 | |
dc.subject | High-risk | en |
dc.subject | Non muscle-invasive bladder cancer | en |
dc.subject | Previous bladder cancer | en |
dc.subject | history | en |
dc.subject | Recurrence | en |
dc.subject | Disease progression | en |
dc.subject | BACILLUS-CALMETTE-GUERIN | en |
dc.subject | CARCINOMA IN-SITU | en |
dc.subject | FOLLOW-UP | en |
dc.subject | STAGE | en |
dc.subject | T1 | en |
dc.subject | TUMORS | en |
dc.subject | TRIALS | en |
dc.subject | TA | en |
dc.subject | IMMUNOTHERAPY | en |
dc.subject | SURVIVAL | en |
dc.subject | Oncology | en |
dc.title | Previous Bladder Cancer History in Patients with High-Risk, Non-muscle-invasive Bladder Cancer Correlates with Recurrence and Progression: Implications of Natural History | en |
dc.type | journalArticle | en |
Files in questo item
Files | Dimensione | Formato | Mostra |
---|---|---|---|
Nessun files in questo item. |